Search Results
Ultra-high risk cytogenetics | Niels van de Donk
Case Review: MM with High-Risk Cytogenetics
Niels Van de Donk | ASCO 2018 | What to do when antibodies fail in MM
Perspectives from the Netherlands - Niels van de Donk, MD | MCRT Webcast Jun 26, 2021
Nico Gagelmann | EBMT 2019 | Outcomes of patients with high-risk cytogenetics undergoing SCT in MM
Niels Van de Donk | EHA 2018 | Immunotherapy in myeloma: why, when and how?
ASH23: Iberdomide Maintenance in EMN26 Study Post Stem-Cell Transplant | Neils van de Donk, MD, PhD
Improving the cure rate of multiple myeloma
Rational for novel combination therapies | Niels van de Donk
Immunotherapy in myeloma: current strategies and future perspectives
Latest Results from the CARTITUDE-2 Study Testing Cilta-cel in Multiple Myeloma Patients
New strategies for durable remission in MM
